US Patent

US9072781 — Morphine formulations

Formulation · Assigned to Becton Dickinson France SA · Expires 2034-03-12 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical formulations, such as injectable morphine formulations, with improved stability and methods for producing and using them.

USPTO Abstract

Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.

Drugs covered by this patent

chembl-chembl2103744 (MORPHINE SULFATE)

Patent Metadata

Patent number: US9072781
Jurisdiction: US
Classification: Formulation
Expires: 2034-03-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Becton Dickinson France SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.